Compare Stitch Fix Inc (SFIX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stitch Fix Inc vs GeneDx Holdings Corp — how do they compare? Stitch Fix Inc trades at $3.94 (market cap $520.36M), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: GeneDx Holdings Corp is far larger — about 3.5× Stitch Fix Inc's market cap, and Stitch Fix Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| SFIX | WGS | |
|---|---|---|
Market Cap | $520.36M | $1.80B |
Sector | Consumer Cyclical | Technology |
52-Week High | $5.83 | $167.51 |
52-Week Low | $3.06 | $34.51 |
Enterprise Value | $408.08M | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stitch Fix (SFIX) trades at $3.84, up 1.32% today, showing signs of stabilization after a challenging period. The stock exhibits a bullish technical signal with improving fundamentals, including narrowing losses and a debt-free balance sheet. Recent quarters show earnings beats, with Q1 2026 actual EPS of -$0.01 beating expectations of -$0.06. Revenue remains stable at $1.27 billion for 2025, while net losses have decreased significantly from -$207 million in 2022 to -$28.74 million in 2025. AI-driven personalization initiatives and active client growth are key positive developments.
The outlook for SFIX is cautiously optimistic as the company's turnaround gains traction. Investment opportunities include potential upside to the $4.75 consensus price target, representing 24% upside, and continued margin improvement. Risks include persistent net losses, competitive pressures in online retail, and sensitivity to consumer spending trends. The stock's low P/S ratio of 0.39 suggests undervaluation if the recovery continues, but execution risks remain substantial.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
